

Immunotherapy Drugs: Global Markets

<https://marketpublishers.com/r/I2D856E078D3EN.html>

Date: March 2021

Pages: 143

Price: US\$ 2,750.00 (Single User License)

ID: I2D856E078D3EN

Abstracts

Report Scope:

The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones.

The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.

The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.

Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and rest of the world (RoW).

Report Includes:

20 data tables and 26 additional tables

An overview of the global market for immunotherapy drugs

Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025

Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth

Description of immunotherapy, combination immunotherapy and discussion on how it targets on cell-mediated adaptive immunity

Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end user and region

Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on future of immunotherapy in cancer

Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy

Discussion on fine tuning versus boosting cancer immunity and early versus advanced stage cancer immunotherapy

Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices

Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Scope of Report
Methodology
Market Estimates
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Vs. Boosting Cancer Immunity
Early Vs. Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Breast Cancer
Colorectal Cancer
Stomach Cancer
Leukemia
Future of Immunotherapy in Cancer
Infectious Diseases
Immunotherapy against Autoimmune Disorders
Immunotherapies against Infectious Diseases
Biologics as Autoimmune Disorder Therapies
Trends in Autoimmune Disorder Therapies
Types of Immunotherapies

Checkpoint Inhibitors
Unmet Medical Needs
New Biomarkers to Stratify Patients
Relapse/Refractory Patients
Treatment Efficacy and Tolerability
Innovative Strategies
Novel Targeted Approaches
Monoclonal Antibodies
Interleukins
Interferons

CHAPTER 4 MARKET DYNAMICS

Strengths of Immunotherapy Market
Growing Aging Population
Rising Incidence of Diseases
Patent Expirations
Growing Pipeline
Drive to Reduce Costs
Government Incentives
Collaborations and Partnerships
Mergers and Acquisitions
Weaknesses of the Immunotherapy Market
Manufacturing Process
Process Definition and Testing and Validation
Lack of Skilled Personnel
Regulatory Guidelines
Patent Litigation
Threats to Immunotherapy Market
Unpredictable Regulatory Landscape
Prescriptions by Medical Practitioners/Pharmacies
Competition
Opportunities in the Immunotherapy Market
Emerging Markets
Technological Innovation and Improved Process Knowledge
Pricing

CHAPTER 5 IMPACT OF COVID-19 ON THE PHARMACEUTICAL INDUSTRY

Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Changes to R&D
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in the Pharmaceutical Industry
Changes in Consumption Trends in Health-related Products

CHAPTER 6 MARKET BREAKDOWN BY PRODUCT TYPE

Overview
Monoclonal Antibodies
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Checkpoint Inhibitors
Pembrolizumab
Companion Diagnostic
Clinical Trial Program
Forecast for Pembrolizumab
Nivolumab (Opdivo)
Companion Diagnostic
Clinical Trial Program
Forecast for Nivolumab
Atezolizumab (Tecentriq)
Companion Diagnostic
Clinical Trial Program
Forecast for Atezolizumab
Avelumab (Bavencio)
Companion Diagnostic
Clinical Trial Program
Forecast for Avelumab
Durvalumab (Imfinzi)
Companion Diagnostic

Clinical Trial Program
Durvalumab Forecasts
Yervoy (Ipilimumab)
Market by Region
Market Revenue
Market Share
Interferons and Interleukins
Market Revenue
Market by Region
Market by Disease Area

CHAPTER 7 MARKET BREAKDOWN BY REGION

Market Overview and Discussion
North America
United States
Canada
Europe
Asia-Pacific
China
Japan
Rest of the World

CHAPTER 8 COMPANY PROFILES

ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
VIATRIS INC. (FORMERLY MYLAN)
NOVARTIS AG
PFIZER INC.
VERTEX PHARMACEUTICALS INC.

List Of Tables

LIST OF TABLES

Summary Table B: Global Market for Immunotherapy Drugs, by Region, Through 2025

Summary Table A: Global Market for Immunotherapy Drugs, by Product Type, Through 2025

Table 1: Stages of Lung Cancer

Table 2: Biologics as Autoimmune Disorder Therapies

Table 3: Adverse Events Associated with Immune-Checkpoint Blockade

Table 4: Evolution of Monoclonal Antibodies

Table 5: Advantages and Disadvantages of Monoclonal Antibodies

Table 6: Murine Monoclonal Antibodies

Table 7: Chimeric Monoclonal Antibodies

Table 8: Humanized Monoclonal Antibodies

Table 9: Human Monoclonal Antibodies

Table 10: Selected Approved Interferon Alpha Analogs

Table 11: Global Market for Immunotherapy Drugs, by Product Type, Through 2025

Table 12: Global Market for Monoclonal Antibodies, by Type, Through 2025

Table 13: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019

Table 14: Global Market for Monoclonal Antibody Drugs, by Region, Through 2025

Table 15: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019

Table 16: Global Market for Checkpoint Inhibitors, 2019-2025

Table 17: Pembrolizumab Approved Indications

Table 18: Nivolumab Approved Indications

Table 19: Atezolizumab Approved Indications

Table 20: Avelumab Approved Indications

Table 21: Durvalumab Approved Indications

Table 22: Global Market of Checkpoint Inhibitors, by Region, Through 2025

Table 23: Global Market Shares for Checkpoint Inhibitors, by Region, 2019

Table 24: Global Market for Interferons and Interleukins, Through 2025

Table 25: Global Market for Interferons and Interleukins, by Region, Through 2025

Table 26: Global Market for Immunotherapy, by Therapeutic Area, Through 2025

Table 27: Global Market for Immunotherapy Drugs, by Region, Through 2025

Table 28: North American Market for Immunotherapy Drugs, by Country, Through 2025

Table 29: North American Market for Immunotherapy Drugs, by Product Type, Through 2025

Table 30: European Market for Immunotherapy Drugs, by Country, Through 2025

Table 31: European Market for Immunotherapy Drugs, by Product Type, Through 2025

Table 32: Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025

Table 33: Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025

Table 34: Chinese Market Statistics

Table 35: Japanese Market Statistics

Table 36: AbbVie: Product Portfolio

Table 37: Amgen: Product Portfolio

Table 38: AstraZeneca: Product Portfolio

Table 39: Bayer AG: Product Portfolio

Table 40: Johnson & Johnson: Product Portfolio

Table 41: Viartis: Product Portfolio

Table 42: Novartis AG: Product Portfolio

Table 43: Pfizer: Product Portfolio

Table 44: Pfizer: Pipeline Product Portfolio

List Of Figures

LIST OF FIGURES

Summary Figure A: Global Market for Immunotherapy Drugs, by Product Type, 2019-2025

Summary Figure B: Global Market for Immunotherapy Drugs, by Region, 2019-2025

Figure 1: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020

Figure 2: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020

Figure 3: Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020

Figure 4: Five-Year Survival Rates, by Lung Cancer Stage

Figure 5: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020

Figure 6: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020

Figure 7: Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020

Figure 8: Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020

Figure 9: Five-Year Survival Rates, by Breast Cancer Stage

Figure 10: Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020

Figure 11: Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020

Figure 12: Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020

Figure 13: Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020

Figure 14: Five-Year Survival Rates, by Colorectal Cancer Stage

Figure 15: Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020

Figure 16: Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012

Figure 17: Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020

Figure 18: Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020

Figure 19: Five-Year Survival Rates, by Stomach Cancer Stage

Figure 20: Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020

Figure 21: Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020

Figure 22: Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020

Figure 23: Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020

Figure 24: Potential Targets for Checkpoint Inhibition in Clinical Evaluation

Figure 25: SWOT Analysis of Immunotherapy Market

Figure 26: Impact of COVID-19 on the Pharmaceutical Industry

Figure 27: Global Market for Immunotherapy Drugs, 2019-2025

Figure 28: Global Market Shares for Immunotherapy Drugs, by Product Type, 2019

Figure 29: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019

Figure 30: Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025

Figure 31: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019

Figure 32: Pembrolizumab Comprehensive Clinical Trial Programs, by Status

Figure 33: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy

Figure 34: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 35: Global Market for Pembrolizumab, 2019-2025

Figure 36: Nivolumab Comprehensive Clinical Trial Programs, by Status

Figure 37: Nivolumab Comprehensive Clinical Trial Programs, by Therapy

Figure 38: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 39: Global Market for Nivolumab, 2019-2025

Figure 40: Atezolizumab Comprehensive Clinical Trial Programs, by Status

Figure 41: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy

Figure 42: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 43: Global Market for Atezolizumab, 2019-2025

Figure 44: Avelumab Comprehensive Clinical Trial Programs, by Status

Figure 45: Avelumab Comprehensive Clinical Trial Programs, by Therapy

Figure 46: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 47: Global Market for Avelumab, 2019-2025

Figure 48: Durvalumab Comprehensive Clinical Trial Programs, by Status

Figure 49: Durvalumab Comprehensive Clinical Trial Programs, by Therapy

Figure 50: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 51: Global Market for Durvalumab, 2019-2025

Figure 52: Global Market for Ipilimumab, 2019-2025

Figure 53: Global Market for Checkpoint Inhibitors, by Region, 2019-2025

Figure 54: Global Market Shares for Checkpoint Inhibitors, by Region, 2019

Figure 55: Global Market for Interferons and Interleukins, by Region, 2019-2025

Figure 56: Global Market Shares for Immunotherapy Drugs, by Region, 2019

Figure 57: North American Market Shares for Immunotherapy Drugs, by Product Type,

2019

Figure 58: European Market for Immunotherapy Drugs, by Country, 2019-2025

Figure 59: European Market for Immunotherapy Drugs, by Product Type, 2019-2025

Figure 60: Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019

Figure 61: AbbVie Inc.: Annual Revenue, 2016-2019

Figure 62: AbbVie: Revenue Share, by Region/Country, 2019

Figure 63: AbbVie: Revenue Share, by Business Unit, 2019

Figure 64: Amgen: Annual Revenue, 2016-2019

Figure 65: Amgen: Revenue Share, by Region/Country, 2019

Figure 66: Amgen: Revenue Share, by Products, 2019

Figure 67: AstraZeneca: Annual Revenue, 2016-2019

Figure 68: AstraZeneca: Revenue Share, by Region/Country, 2019

Figure 69: AstraZeneca: Revenue Share, by Business Unit, 2019

Figure 70: Bayer AG: Annual Revenue, 2016-2019

Figure 71: Bayer AG: Revenue Share, by Region, 2019

Figure 72: Bayer AG: Revenue Share, by Business Unit, 2019

Figure 73: Bristol Myers Squibb: Annual Revenue, 2016-2019

Figure 74: Bristol Myers Squibb: Revenue Share, by Region/Country, 2019

Figure 75: Bristol Myers Squibb: Revenue Share, by Brands, 2019

Figure 76: Hoffmann-La Roche: Annual Revenue, 2016-2019

Figure 77: Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019

Figure 78: Hoffmann-La Roche: Revenue Share, by Business Segment, 2019

Figure 79: Johnson & Johnson: Annual Revenue, 2016-2019

Figure 80: Johnson & Johnson: Revenue Share, by Region/Country, 2019

Figure 81: Johnson & Johnson: Revenue Share, by Business Unit, 2019

Figure 82: Viatrix: Annual Revenue, 2016-2019

Figure 83: Viatrix: Revenue Share, by Region, 2019

Figure 84: Viatrix: Revenue Share, by Business Unit, 2019

Figure 85: Novartis AG: Annual Revenue, 2015-2019

Figure 86: Novartis AG: Revenue Share, by Region/Country, 2019

Figure 87: Novartis AG: Revenue Share, by Business Segment, 2019

Figure 88: Pfizer: Annual Revenue, 2016-2019

Figure 89: Pfizer: Revenue Share, by Region/Country, 2019

Figure 90: Pfizer: Revenue Share, by Business Segment, 2019

Figure 91: Vertex Pharmaceuticals: Annual Revenue, 2016-2019

Figure 92: Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019

Figure 93: Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019

I would like to order

Product name: Immunotherapy Drugs: Global Markets

Product link: <https://marketpublishers.com/r/l2D856E078D3EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2D856E078D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970